医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TGR BioSciences Announces License Agreement With Abcam

2013年09月23日 PM03:25
このエントリーをはてなブックマークに追加


 

ADELAIDE, Australia

TGR BioSciences Pty Ltd (TGR), a leading developer of advanced cell-based assay technologies, is pleased to announce a license agreement with Abcam plc, of Cambridge, UK, a producer and distributor of high quality protein research tools. Under the agreement Abcam will develop and manufacture immunoassay products that incorporate TGR’s proprietary CaptSure™ assay technology. Immunoassays incorporating CaptSure are highly sensitive, offer considerable time savings, and are easy to perform when compared with conventional sandwich immunoassays.

James Murray, General Manager of Abcam Eugene commented: “We are pleased to have signed the license agreement with TGR. This innovative technology will enable Abcam to continue to develop its high quality immunoassay range by providing even greater choice to customers.”

“We’re extremely pleased that Abcam, a company at the forefront of product supply and support, has recognised the significant advantages afforded by our CaptSure immunoassay technology,” says Anne Hinton, CEO at TGR BioSciences. “Abcam is recognized around the world for providing the highest quality products and services to the Life Science community, and we are very excited to see Abcam incorporating our technology in their immunoassay products.”

About TGR BioSciences:

TGR BioSciences Pty Ltd (TGR) is an innovative private biotechnology company based in Adelaide, South Australia, specializing in the development of immunoassay technologies and products to serve the global research and discovery markets. TGR has on market a broad portfolio of state-of-the-art assays for cell-based analysis of GPCRs, kinases and cell signalling pathways, supplying major pharmaceutical and biotechnology companies, and academic laboratories worldwide. TGR is actively developing further novel cell-based analysis technologies to advance research in other key therapeutic areas.

For more information, please visit www.tgrbio.com.

About the CaptSure™ technology:

TGR’s proprietary CaptSure™ technology enables solution-phase delivery of antibody pairs in sandwich immunoassays, allowing the simultaneous formation and immobilisation of the analyte immunocomplex in a single assay incubation. Assays can be run in as little as 1 hour, require only a single wash cycle, and provide an extremely sensitive means for quantitation of proteins. Furthermore, there is no requirement for specialized instrumentation, with the assays using standard laboratory plate readers for signal detection.

About Abcam:

Abcam plc is a provider of protein research tools and services, with an unrivalled range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work

Headquartered in Cambridge, UK, Abcam has global subsidiary offices enabling local services, mulit-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 680 FTEs. Abcam was admitted to AIM in 2005 (AIM:ABC).

To find out more, please visit www.abcam.com.

About Abcam Eugene:

Formerly known as MitoSciences, Abcam Eugene is a centre of excellence for assay development, supporting critical research areas in cancer, neurodegeneration and metabolic disorders.

CONTACT

TGR BioSciences
Anne Hinton, +61 (0)8 8354 6174
CEO
ahinton@tgrbio.com
or
For
Abcam

Francesca Axe, +44 (0) 1223 69600

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent